[go: up one dir, main page]

HK1122997A1 - Vaccines comprising purified surface antigens prepared from influenza viruses grown in cell culture, adjuvanted with squalene - Google Patents

Vaccines comprising purified surface antigens prepared from influenza viruses grown in cell culture, adjuvanted with squalene

Info

Publication number
HK1122997A1
HK1122997A1 HK09100730.6A HK09100730A HK1122997A1 HK 1122997 A1 HK1122997 A1 HK 1122997A1 HK 09100730 A HK09100730 A HK 09100730A HK 1122997 A1 HK1122997 A1 HK 1122997A1
Authority
HK
Hong Kong
Prior art keywords
adjuvanted
squalene
vaccines
cell culture
surface antigens
Prior art date
Application number
HK09100730.6A
Other languages
English (en)
Inventor
Rino Rappuoli
Derek O'hagan
Giudice Giuseppe Del
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Publication of HK1122997A1 publication Critical patent/HK1122997A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
HK09100730.6A 2005-11-04 2009-01-23 Vaccines comprising purified surface antigens prepared from influenza viruses grown in cell culture, adjuvanted with squalene HK1122997A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US73402605P 2005-11-04 2005-11-04
US73565805P 2005-11-11 2005-11-11
PCT/GB2006/004128 WO2007052055A1 (fr) 2005-11-04 2006-11-06 Vaccins avec adjuvant comprenant des antigenes sans virions prepares a partir de virus influenza eleves en culture cellulaire

Publications (1)

Publication Number Publication Date
HK1122997A1 true HK1122997A1 (en) 2009-06-05

Family

ID=37831416

Family Applications (1)

Application Number Title Priority Date Filing Date
HK09100730.6A HK1122997A1 (en) 2005-11-04 2009-01-23 Vaccines comprising purified surface antigens prepared from influenza viruses grown in cell culture, adjuvanted with squalene

Country Status (15)

Country Link
US (2) US10842867B2 (fr)
EP (3) EP3714900A1 (fr)
JP (1) JP2009514838A (fr)
AU (1) AU2006310336B2 (fr)
CA (1) CA2628152C (fr)
DK (1) DK2368572T3 (fr)
ES (2) ES2792398T3 (fr)
FI (1) FIC20240033I1 (fr)
FR (1) FR20C1043I1 (fr)
HK (1) HK1122997A1 (fr)
HU (1) HUE051122T2 (fr)
NZ (1) NZ567981A (fr)
PL (2) PL1945252T3 (fr)
PT (1) PT2368572T (fr)
WO (1) WO2007052055A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009000660A (es) 2006-07-17 2009-04-08 Glaxosmithkline Biolog Sa Vacuna de influenza.
DK2422810T3 (da) * 2006-07-17 2014-11-24 Glaxosmithkline Biolog Sa Influenzavaccine
US9452209B2 (en) 2007-04-20 2016-09-27 Glaxosmithkline Biologicals Sa Influenza vaccine
SG11202003793WA (en) 2017-10-30 2020-05-28 Baxalta GmbH Environmentally compatible detergents for inactivation of lipid-enveloped viruses
MX2021010194A (es) 2019-02-25 2022-01-24 Seqirus Uk Ltd Vacunas contra la influenza multivalentes adyuvantadas.
CN114929270A (zh) 2019-11-07 2022-08-19 塞其里斯英国有限公司 用于生产具有减小的颗粒大小的病毒疫苗的组合物和方法

Family Cites Families (168)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4060082A (en) 1976-08-16 1977-11-29 Mpl, Inc. Dual-ingredient medication dispenser
US4500513A (en) 1979-05-15 1985-02-19 Miles Laboratories, Inc. Influenza vaccine production in liquid cell culture
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
US5916588A (en) 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
US6090406A (en) 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US4680338A (en) 1985-10-17 1987-07-14 Immunomedics, Inc. Bifunctional linker
US5011828A (en) 1985-11-15 1991-04-30 Michael Goodman Immunostimulating guanine derivatives, compositions and methods
JPS62201573A (ja) 1986-02-27 1987-09-05 Shionogi & Co Ltd 家禽用インフルエンザワクチン
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
AU627226B2 (en) 1988-08-25 1992-08-20 Liposome Company, Inc., The Influenza vaccine and novel adjuvants
US5238944A (en) 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
US4929624A (en) 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
WO1990014837A1 (fr) * 1989-05-25 1990-12-13 Chiron Corporation Composition d'adjuvant comprenant une emulsion de gouttelettes d'huile d'une taille inferieure au micron
US4988815A (en) 1989-10-26 1991-01-29 Riker Laboratories, Inc. 3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines
US5658731A (en) 1990-04-09 1997-08-19 Europaisches Laboratorium Fur Molekularbiologie 2'-O-alkylnucleotides as well as polymers which contain such nucleotides
US5389640A (en) 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
CA2289219C (fr) 1991-03-01 2003-05-20 Minnesota Mining And Manufacturing Company 1h-imidazo-[4,5-c]quinoline-4-amines substituees en 1 et en 2
JPH0614756Y2 (ja) 1991-06-26 1994-04-20 株式会社アルテ 組み立て式の２室式容器兼用注射器
US5936076A (en) 1991-08-29 1999-08-10 Kirin Beer Kabushiki Kaisha αgalactosylceramide derivatives
US5268376A (en) 1991-09-04 1993-12-07 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5266575A (en) 1991-11-06 1993-11-30 Minnesota Mining And Manufacturing Company 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
MY111880A (en) 1992-03-27 2001-02-28 Smithkline Beecham Biologicals S A Hepatitis vaccines containing 3-0 deacylated monophosphoryl lipid a
IL105325A (en) 1992-04-16 1996-11-14 Minnesota Mining & Mfg Immunogen/vaccine adjuvant composition
DK0761231T3 (da) 1992-06-25 2000-05-08 Smithkline Beecham Biolog Vaccinepræparat indeholdende adjuvanser
US5395937A (en) 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
DE69405551T3 (de) 1993-03-23 2005-10-20 Smithkline Beecham Biologicals S.A. 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen
ATE195735T1 (de) 1993-07-15 2000-09-15 Minnesota Mining & Mfg Imidazo (4,5-c)pyridin-4-amine
US5352784A (en) 1993-07-15 1994-10-04 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
ES2370937T3 (es) 1993-09-13 2011-12-23 Protein Sciences Corporation Un método para producir vacunas antigripales polivalentes a base de hemaglutinina.
US5762939A (en) 1993-09-13 1998-06-09 Mg-Pmc, Llc Method for producing influenza hemagglutinin multivalent vaccines using baculovirus
WO1995011700A1 (fr) 1993-10-29 1995-05-04 Pharmos Corp. Emulsions submicroniques utilisees comme adjuvants de vaccin
GB9326174D0 (en) 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5824536A (en) 1994-08-23 1998-10-20 St. Jude Children's Research Hospital Influenza virus replicated in mammalian cell culture and vaccine production
US5496284A (en) 1994-09-27 1996-03-05 Waldenburg; Ottfried Dual-chamber syringe & method
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
EP2290053A1 (fr) 1994-11-10 2011-03-02 Baxter Healthcare S.A. Procédé pour la production du virus de la grippe dans un milieu de culture céllulaire sans protéines
US5482936A (en) 1995-01-12 1996-01-09 Minnesota Mining And Manufacturing Company Imidazo[4,5-C]quinoline amines
GB9503863D0 (en) 1995-02-25 1995-04-19 Smithkline Beecham Biolog Vaccine compositions
GB9620795D0 (en) 1996-10-05 1996-11-20 Smithkline Beecham Plc Vaccines
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
DE19612966B4 (de) 1996-04-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co. Kg MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren
DE19612967A1 (de) * 1996-04-01 1997-10-02 Behringwerke Ag Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren
AU3186297A (en) 1996-07-05 1998-02-02 Debiotech S.A. Dual-chamber syringe for mixing two substances prior to injection
AU4992197A (en) 1996-10-11 1998-05-11 Regents Of The University Of California, The Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
AT405939B (de) 1997-02-24 1999-12-27 Immuno Ag Verfahren zur inaktivierung von lipidumhüllten viren
DE69841122D1 (de) 1997-03-10 2009-10-15 Coley Pharm Gmbh Verwendung von nicht-methyliertem CpG Dinukleotid in Kombination mit Aluminium als Adjuvantien
US6818222B1 (en) 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
TW570803B (en) 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
AU7126998A (en) 1997-04-16 1998-11-11 Connaught Laboratories Inc. Anti-influenza compositions supplemented with neuraminidase
US6080725A (en) 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
CA2302554C (fr) 1997-09-05 2007-04-10 Smithkline Beecham Biologicals S.A. Emulsions huile-dans-l'eau contenant des saponines
AU9785598A (en) 1997-10-03 1999-04-27 Texas Pharmaceuticals, Inc. Improved dual chamber syringe apparatus
US5971953A (en) 1998-01-09 1999-10-26 Bachynsky; Nicholas Dual chamber syringe apparatus
GB9725084D0 (en) 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
HUP0101139A3 (en) 1997-12-02 2003-11-28 Powderject Vaccines Inc Madiso Transdermal delivery of particulate vaccine compositions
US6782510B1 (en) 1998-01-27 2004-08-24 John N. Gross Word checking tool for controlling the language content in documents using dictionaries with modifyable status fields
KR20010042573A (ko) 1998-04-09 2001-05-25 장 스테판느 애쥬번트 조성물
CA2330610A1 (fr) 1998-05-07 1999-11-11 Corixa Corporation Composition d'adjuvant et procedes d'utilisation de celle-ci
US6562798B1 (en) 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
US6110929A (en) 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
DE19835749C1 (de) 1998-08-07 2000-02-03 Dieter Perthes Fertig-Spritze für nicht-stabile Arzneimittel
US6544785B1 (en) 1998-09-14 2003-04-08 Mount Sinai School Of Medicine Of New York University Helper-free rescue of recombinant negative strand RNA viruses
AT408615B (de) * 1998-09-15 2002-01-25 Immuno Ag Neue influenzavirus-impfstoffzusammensetzung
DK1126876T3 (da) 1998-10-16 2007-07-02 Glaxosmithkline Biolog Sa Adjuvanssystemer og vacciner
US20030130212A1 (en) 1999-01-14 2003-07-10 Rossignol Daniel P. Administration of an anti-endotoxin drug by intravenous infusion
US6551600B2 (en) 1999-02-01 2003-04-22 Eisai Co., Ltd. Immunological adjuvant compounds compositions and methods of use thereof
ATE276199T1 (de) 1999-02-03 2004-10-15 Biosante Pharmaceuticals Inc Methoden zur herstellung von therapeutische kalzium-phosphat partikeln
AU2875700A (en) * 1999-02-26 2000-09-14 Chiron Corporation Microemulsions with adsorbed macromoelecules and microparticles
CA2365416C (fr) 1999-03-26 2011-06-14 Vical Incorporated Compositions d'adjuvant et methodes permettant d'accentuer les reponses immunitaires a des vaccins a base de polynucleotides
EP2345716B1 (fr) 1999-04-06 2015-01-14 Wisconsin Alumni Research Foundation Virus de la grippe recombinant pour vaccins et thérapie génétique
IL145982A0 (en) 1999-04-19 2002-07-25 Smithkline Beecham Biolog Vaccines
US6331539B1 (en) 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
DE122008000057I1 (de) * 1999-07-14 2009-04-09 Sinai School Medicine In vitro-rekonstitution von segmentierten negativstrang-rna-viren
PL355232A1 (en) 1999-09-24 2004-04-05 Smithkline Beecham Biologicals S.A. Adjuvant comprising a polyxyethylene alkyl ether or ester and at least one nonionic surfactant
JP4763197B2 (ja) 1999-09-24 2011-08-31 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 新規ワクチン
KR20020038770A (ko) 1999-09-24 2002-05-23 장 스테판느 애쥬번트로서의 폴리옥시에틸렌 소르비탄 에스테르와옥톡시놀의 조합물의 용도 및 백신과 관련된 이의 용도
WO2001022972A2 (fr) 1999-09-25 2001-04-05 University Of Iowa Research Foundation Acides nucleiques immunostimulateurs
GB9923176D0 (en) 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
US20040109874A1 (en) 1999-11-10 2004-06-10 Powderject Vaccines, Inc. Induction of mucosal immunity by vaccination via the skin route
EP1311288A1 (fr) 2000-01-20 2003-05-21 Ottawa Health Research Institute Acides nucleiques immunostimulateurs permettant d'induire une reponse immunitaire th2
US6825036B2 (en) 2000-03-03 2004-11-30 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Cell usable in serum-free culture and suspension culture and process for producing virus for vaccine by using the cell
WO2001080836A1 (fr) 2000-04-26 2001-11-01 Biovector Therapeutics Utilisation de vecteurs particulaires dans l'immunomodulation
ATE420189T1 (de) 2000-04-28 2009-01-15 St Jude Childrens Res Hospital Dna-transfektionssystem zur erzeugung von infektiösen negativsträngigen rna virus
FR2808803B1 (fr) 2000-05-11 2004-12-10 Agronomique Inst Nat Rech Cellules es modifiees et gene specifique de cellules es
US6756383B2 (en) 2000-09-01 2004-06-29 Chiron Corporation Heterocyclic derivatives of quinolinone benimidazoles
DE60115069T2 (de) 2000-09-11 2006-08-03 Chiron Corp., Emeryville Chinolinonderivate als tyrosin-kinase inhibitoren
AUPR007600A0 (en) * 2000-09-13 2000-10-05 Kajlich, Anti Equipment for faster swimming pools
KR100894767B1 (ko) 2000-09-26 2009-04-24 이데라 파마슈티칼즈, 인코포레이티드 화학적인 위치 변화에 의해 면역자극 올리고누클레오티드유사체의 면역자극 활성을 조절하는 방법
GB0024089D0 (en) 2000-10-02 2000-11-15 Smithkline Beecham Biolog Novel compounds
JP2004511527A (ja) 2000-10-18 2004-04-15 グラクソスミスクライン　バイオロジカルズ　ソシエテ　アノニム ワクチン
GB0025577D0 (en) 2000-10-18 2000-12-06 Smithkline Beecham Biolog Vaccine
US6664260B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Heterocyclic ether substituted imidazoquinolines
US6677347B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Sulfonamido ether substituted imidazoquinolines
US6660735B2 (en) 2000-12-08 2003-12-09 3M Innovative Properties Company Urea substituted imidazoquinoline ethers
US6667312B2 (en) 2000-12-08 2003-12-23 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6664265B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6664264B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6677348B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Aryl ether substituted imidazoquinolines
US6660747B2 (en) 2000-12-08 2003-12-09 3M Innovative Properties Company Amido ether substituted imidazoquinolines
UA74852C2 (en) 2000-12-08 2006-02-15 3M Innovative Properties Co Urea-substituted imidazoquinoline ethers
US7018638B2 (en) 2000-12-19 2006-03-28 Wyeth Mycoplasma hyopneumoniae bacterin vaccine
EP1361889A1 (fr) 2001-02-23 2003-11-19 GlaxoSmithKline Biologicals S.A. Nouveau vaccin
DK1361890T3 (da) 2001-02-23 2011-06-27 Glaxosmithkline Biolog Sa Influenzavaccineformuleringer til intradermal indgift
EP1372706B1 (fr) 2001-03-09 2010-12-01 ID Biomedical Corporation of Quebec Adjuvant de vaccin proteosome-liposaccharide
TWI228420B (en) 2001-05-30 2005-03-01 Smithkline Beecham Pharma Gmbh Novel vaccine composition
US7361352B2 (en) 2001-08-15 2008-04-22 Acambis, Inc. Influenza immunogen and vaccine
DE10144903A1 (de) 2001-09-12 2003-03-27 Chiron Behring Gmbh & Co Vermehrung von Viren in Zellkultur
DE10144906B4 (de) 2001-09-12 2013-11-28 Novartis Vaccines And Diagnostics Gmbh Verfahren zur großtechnischen Herstellung von Impfstoffen
WO2003035836A2 (fr) 2001-10-24 2003-05-01 Hybridon Inc. Modulation des proprietes immunostimulantes de composes a base d'oligonucleotides par presentation optimale d'extremites 5'
FR2832423B1 (fr) 2001-11-22 2004-10-08 Vivalis Systeme d'expression de proteines exogenes dans un systeme aviaire
KR100718371B1 (ko) 2001-11-27 2007-05-14 애나디스 파마슈티칼스, 인코포레이티드 ３-β-Ｄ-리보푸라노실티아졸로[４,５-ｄ]피리디민누클레오시드 및 이의 용도
US7321033B2 (en) 2001-11-27 2008-01-22 Anadys Pharmaceuticals, Inc. 3-B-D-ribofuranosylthiazolo [4,5-d] pyrimidine nucleosides and uses thereof
US6677349B1 (en) 2001-12-21 2004-01-13 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
FR2836924B1 (fr) 2002-03-08 2005-01-14 Vivalis Lignees de cellules aviaires utiles pour la production de substances d'interet
US6861410B1 (en) * 2002-03-21 2005-03-01 Chiron Corporation Immunological adjuvant compositions
CA2480638C (fr) 2002-03-29 2013-02-12 Chiron Corporation Benzazoles substitues et leur utilisation en tant qu'inhibiteurs de la kinase raf
US6743920B2 (en) 2002-05-29 2004-06-01 3M Innovative Properties Company Process for imidazo[4,5-c]pyridin-4-amines
CA2493690C (fr) 2002-06-13 2011-11-08 New York University C-glycolipide de synthese et utilisation de celui-ci pour le traitement du cancer, des maladies infectieuses et des maladies auto-immunes
WO2004018455A1 (fr) 2002-08-23 2004-03-04 Chiron Corporation Inhibiteurs de la glycogene synthase kinase 3 a base de pyrrole
US7521062B2 (en) 2002-12-27 2009-04-21 Novartis Vaccines & Diagnostics, Inc. Thiosemicarbazones as anti-virals and immunopotentiators
CA2513655C (fr) 2003-01-21 2011-11-22 Chiron Corporation Utilisation de composes de tryptanthrine dans la potentialisation immunologique
GB0301554D0 (en) 2003-01-23 2003-02-26 Molecularnature Ltd Immunostimulatory compositions
CN101214375B (zh) 2003-03-24 2011-04-06 英特塞尔股份公司 改进的疫苗
WO2004087153A2 (fr) 2003-03-28 2004-10-14 Chiron Corporation Utilisation de petites molecules de composes pour une immunopotentialisation
US7731967B2 (en) 2003-04-30 2010-06-08 Novartis Vaccines And Diagnostics, Inc. Compositions for inducing immune responses
EP1651265B1 (fr) 2003-07-24 2008-04-23 Merial Limited Formulation vaccinale comportant une émulsion d'huile en eau
RU2236257C1 (ru) 2003-09-15 2004-09-20 Косяков Константин Сергеевич Синтетический иммуноген для терапии и профилактики злоупотреблений наркотическими и психоактивными веществами
US7771726B2 (en) 2003-10-08 2010-08-10 New York University Use of synthetic glycolipids as universal adjuvants for vaccines against cancer and infectious diseases
EP1528101A1 (fr) 2003-11-03 2005-05-04 ProBioGen AG Lignées cellulaires aviaires immortalisées pour la production de virus
US8673634B2 (en) 2003-11-13 2014-03-18 Massachusetts Eye & Ear Infirmary Method for the treatment of hearing loss
EP1550458A1 (fr) 2003-12-23 2005-07-06 Vectron Therapeutics AG Adjuvants liposomals synergiques
EP1722815A1 (fr) * 2004-03-09 2006-11-22 Chiron Corporation Vaccins antigrippaux
EP1728528B1 (fr) 2004-03-23 2013-06-19 Nipro Corporation Seringue pre-remplie
AU2005235080A1 (en) 2004-03-31 2005-11-03 New York University Novel synthetic C-glycolipids, their synthesis and use to treat infections, cancer and autoimmune diseases
DK1742659T3 (da) 2004-04-05 2013-06-03 Zoetis P Llc Mikrofluidiserede olie-i-vand-emulsioner og vaccinesammensætninger
WO2005113756A1 (fr) 2004-05-14 2005-12-01 Glaxosmithkline Biologicals S.A. Methode
WO2005113758A1 (fr) 2004-05-20 2005-12-01 Id Biomedical Corporation Procédé pour la fabrication d’un vaccin contre la grippe
ATE491467T1 (de) 2004-05-28 2011-01-15 Glaxosmithkline Biolog Sa Impfstoffzusammensetzungen mit virosomen und einem saponin-adjuvans
CA2571421A1 (fr) 2004-06-24 2006-01-05 Nicholas Valiante Composes utilises pour l'immunopotentialisation
DE102004032251B4 (de) 2004-07-03 2008-05-29 Daimler Ag Vorrichtung zur Abscheidung von Wasser und zur Ausfilterung von Verunreinigungen
SI1789084T1 (sl) 2004-09-09 2011-03-31 Novartis Vaccines & Diagnostic Zmanjševanje potencialnih iatrogenih tveganj, povezanih z influenčnimi cepivi
US20070292386A9 (en) 2004-12-02 2007-12-20 Campbell Robert L Vaccine formulations for intradermal delivery comprising adjuvants and antigenic agents
AU2005322353B2 (en) 2004-12-23 2011-09-01 Medimmune, Llc Non-tumorigenic MDCK cell line for propagating viruses
RU2435855C2 (ru) 2004-12-24 2011-12-10 Солвей Байолоджикалз Б.В. Способ продуцирования репликативной частицы вируса гриппа, композиция клеток (варианты), композиция клеточной культуры и ее применение
WO2006100111A1 (fr) 2005-03-23 2006-09-28 Glaxosmithkline Biologicals S.A. Composition
FR2884255B1 (fr) 2005-04-11 2010-11-05 Vivalis Utilisation de lignees de cellules souches aviaires ebx pour la production de vaccin contre la grippe
US7691368B2 (en) 2005-04-15 2010-04-06 Merial Limited Vaccine formulations
AR054822A1 (es) 2005-07-07 2007-07-18 Sanofi Pasteur Emulsion inmuno adyuvante
JP2009500869A (ja) 2005-07-11 2009-01-08 ブルックス オートメーション インコーポレイテッド オンザフライ（ｏｎｔｈｅｆｌｙ）ワークピースセンタリングを備えた装置
US7425336B2 (en) * 2005-08-25 2008-09-16 Mevial Limited Canine influenza vaccines
US7384642B2 (en) * 2005-08-25 2008-06-10 Merial Limited Canine influenza vaccines
CA2628397C (fr) * 2005-11-04 2013-08-20 Novartis Vaccines And Diagnostics S.R.L. Modification de l'equilibre th1/th2 dans des vaccins antigrippaux sous-unitaires avec adjuvants
EA014190B1 (ru) * 2005-11-04 2010-10-29 Новартис Вэксинс Энд Диагностикс Срл Вакцины против гриппа, адсорбированные на алюминиевых адъювантах, для немедленного приёма
CA2657989A1 (fr) * 2006-06-15 2007-12-21 Novartis Ag Regime de vaccination multidose a adjuvant limite contre la grippe
NZ575271A (en) 2006-09-11 2011-09-30 Novartis Ag Making influenza virus vaccines without using eggs
US9452209B2 (en) 2007-04-20 2016-09-27 Glaxosmithkline Biologicals Sa Influenza vaccine
US8506966B2 (en) * 2008-02-22 2013-08-13 Novartis Ag Adjuvanted influenza vaccines for pediatric use
SI2356983T1 (sl) * 2009-12-03 2013-05-31 Novartis Ag KroĹľenje komponent med homogenizacijo emulzij

Also Published As

Publication number Publication date
ES2792398T3 (es) 2020-11-11
EP2368572A2 (fr) 2011-09-28
JP2009514838A (ja) 2009-04-09
WO2007052055A1 (fr) 2007-05-10
FIC20240033I1 (fi) 2024-10-18
EP2368572B1 (fr) 2020-03-04
HUE051122T2 (hu) 2021-03-01
NZ567981A (en) 2011-10-28
DK2368572T3 (da) 2020-05-25
EP1945252A1 (fr) 2008-07-23
PL1945252T3 (pl) 2013-11-29
US10842867B2 (en) 2020-11-24
EP2368572A3 (fr) 2013-04-24
US20090220544A1 (en) 2009-09-03
FR20C1043I1 (fr) 2020-10-16
CA2628152A1 (fr) 2007-05-10
ES2420829T3 (es) 2013-08-27
PT2368572T (pt) 2020-06-16
AU2006310336A1 (en) 2007-05-10
PL2368572T3 (pl) 2020-11-16
EP3714900A1 (fr) 2020-09-30
EP1945252B1 (fr) 2013-05-29
AU2006310336B2 (en) 2011-02-03
CA2628152C (fr) 2016-02-02
US20240299537A1 (en) 2024-09-12

Similar Documents

Publication Publication Date Title
WO2012177924A3 (fr) Mutants du virus de la grippe et utilisations
WO2008076371A3 (fr) Procédé destiné à répliquer le virus de la grippe en culture
IL203869A (en) Method of Preparing a Containing a Virus or Antigen Antigen, Various Aspects Related to This Method, Uses of a Method and Vaccination of a Split Virus Prepared by This Method
IL190775A (en) Influenza virus-like particles, vaccines containing them and their uses
SG2014007934A (en) Modified influenza virus for monitoring and improving vaccine efficiency
WO2007085969A3 (fr) Vaccins contre la grippe contenant des hémaglutinines et des protéines matricielles
IL189329A0 (en) Vaccination against dengue virus infection
HK1144374A1 (en) Decreasing potential latrogenic risks associated with influenza vaccines
WO2007052059A3 (fr) Modification de l'equilibre th1/th2 dans des vaccins antigrippaux sous-unitaires avec adjuvants
HK1122997A1 (en) Vaccines comprising purified surface antigens prepared from influenza viruses grown in cell culture, adjuvanted with squalene
HK1123055A1 (en) Hepatitis c virus nucleic acid vaccine
HK1245334A1 (zh) 改善的用於人乳頭狀瘤病毒的疫苗及其使用方法
ZA200905952B (en) Lyophilized preparation comprising influenza vaccine,and method for preparation thereof
CL2011000913A1 (es) Vacuna combinada estable y completamente liquida que comprende antigenos difterico, tetanico, pertusico de celulas completas, y virus de poliomielitis y opcionalmente uno o mas antigenos seleccionados entre haemophilus influenzae y hepatitis; y proceso de fabricacion.
ZA201004337B (en) Bluetongue virus vaccine and immunogenic compositions, methods of use and methods of producing the same
ZA201600550B (en) Compositions, methods and uses for inducing viral growth
WO2006063053A3 (fr) Methodes de preparation de vaccins contre la grippe
WO2007082734A3 (fr) Vaccin anti-grippal
GB0706912D0 (en) Novel viral vaccines
WO2006017206A3 (fr) Vaccin contre les flavivirus
UA100849C2 (ru) Способ репликации вируса гриппа в культуре
AP2007004226A0 (en) HIV vaccine
WO2010110931A3 (fr) Vaccins glycoconjugués
ZA200802176B (en) Vaccination against dengue virus infection
IL185932A (en) Viral antigens, conjugates and preparations containing them, for vaccination and diagnosis